Osteoporosis International

, Volume 23, Issue 2, pp 733–741

Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™


    • Division of Epidemiology, Department of Family and Preventive MedicineSchool of Medicine, University of California San Diego
  • S. W. Wade
    • Wade Outcomes Research and Consulting
  • T. P. Do
    • Amgen Inc.
  • S. Satram-Hoang
    • Amgen Inc.
  • R. Stewart
    • Amgen Inc.
  • G. Gao
    • Amgen Inc.
  • D. Macarios
    • Amgen Inc.
Original Article

DOI: 10.1007/s00198-011-1620-3

Cite this article as:
Barrett-Connor, E., Wade, S.W., Do, T.P. et al. Osteoporos Int (2012) 23: 733. doi:10.1007/s00198-011-1620-3



Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.


Non-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.


Data from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.


Median TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n = 1,182; median = 87.5 (Q1 = 75.0, Q3 = 100.0)] and lowest for global satisfaction [n = 2,340; median = 64.0 (Q1 = 55.7, Q3 = 77.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI = 0.63–0.85; effectiveness 0.82, 95% CI = 0.70–0.97; and global satisfaction 0.73, 95% CI = 0.63–0.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR = 0.60, 95% CI = 0.37–0.97).


Lower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year of follow-up.


DiscontinuationMedicationPostmenopausal osteoporosisSwitchingTreatment satisfaction

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011